Safety and efficacy of oral antiplatelet for patients who had acute ischaemic stroke undergoing endovascular therapy

Xiaochuan Huo, 1 Raynald, 1 Jing Jing, 2,3,4 Anxin Wang, 2,3,4 Dapeng Mo, 5 Feng Gao, 5 Ning Ma, 5 Yilong Wang, 2,3,4 Yongjun Wang, 2,3,4 Zhongrong Miao 6

ABSTRACT
Background and purpose To investigate the safety and efficacy of oral antiplatelet therapy (APT) for patients who had acute ischaemic stroke (AIS), receiving endovascular therapy (EVT).

Methods Patients were divided into non-APT group and APT (single APT or dual APT (DAPT)) group. The safety and efficacy endpoints at 3-month follow-up were symptomatic intracranial haemorrhage (sICH), recanalisation rate, clinical outcome and mortality.

Results Among 915 patients who had AIS, those in APT group (n=199) showed shorter puncture-to-recanalisation time, lower frequency of intravenous thrombolysis and more use of tiroliban compared with those in non-antiplatelet group (n=716) (p<0.05 for all). Oral APT was found to be associated with superior clinical outcome compared with non-APT (APT (44.2%) versus non-APT (41.1%), adjusted OR=2.605, 95% CI 1.244 to 5.455, p=0.011). DAPT showed superior clinical outcome compared with non-APT (DAPT (56.5%) versus non-APT (41.1%), adjusted OR=5.405, 95% CI 1.614 to 18.102, p=0.006) and lower risk of mortality at 3-month follow-up (DAPT (4.8%) versus non-DAPT (17.7%), adjusted OR=0.008, 95% CI 0.000 to 0.441, p=0.019). There was no significant difference in sICH between the two groups.

Conclusions Oral APT prior to undergoing EVT is safe and may accompany with superior clinical outcomes. DAPT may associate with superior clinical outcomes and lower risk of mortality.

INTRODUCTION
Despite the advantages of antiplatelet therapy (APT) in terms of reducing the risk of stroke and its recurrence, there is still a controversy regarding the potential risk of increased bleeding. 1-4 To date, a prospective cohort study was conducted to evaluate the safety and efficacy of dual APT (DAPT) prior to intravenous thrombolysis (IVT) for patients who had acute ischaemic stroke (AIS). They reported that DAPT is safe and is not associated with higher rates of bleeding and 3-month mortality. 5 This result was confirmed by a recent meta-analysis, which demonstrated that the oral antiplatelet is safe and is not associated with higher risk of adverse outcomes in patients who had AIS receiving IVT. 6

Endovascular therapy (EVT) has been confirmed by its efficacy to treat AIS with large vessel occlusion in the well-known randomised controlled trials. 9-14 However, few studies with limited number of patients have evaluated the safety and efficacy of APT for patients who had AIS receiving EVT. 15-17 Another meta-analysis demonstrated that the randomised controlled trials are warranted to address a question whether the potentially higher risk of symptomatic intracranial haemorrhage (sICH) could be outweighed by improved functional outcome. 18 Thus, safety and efficacy of APT for patients who had AIS undergoing EVT need to be further assessed.

Hence, the present study aimed to evaluate the safety and efficacy of oral APT for patients who had AIS undergoing EVT.

METHODS
Study design and patient enrolment
All patients were enrolled from the Acute Ischemic Stroke Cooperation group of Endovascular Treatment (ANGEL) registry, a multicentre nationwide prospective study protocol that recruited 917 patients who had AIS to evaluate the EVT delivery and to improve EVT in clinical practice in Chinese population. The details related to ANGEL study protocol, including design, inclusion/exclusion criteria, data collection and endovascular procedures, are in accordance with our previous research. 19

Data collection
Patient’s baseline data, such as age, sex, systolic blood pressure (SBP), the National Institutes of Health Stroke Scale (NIHSS) score, Alberta Stroke Program Early CT Score (ASPECTS), time intervals (onset-to-door (OTD), door-to-puncture, puncture-to-recanalisation (PTR), onset-to-puncture and onset-to-recanalisation, were recorded within 24 hours after admission. The assessment of medical records included history of
atrial fibrillation (confirmed by ECG), diabetes mellitus, previous stroke, hypertension, smoking and drinking. The aetiology of the stroke based on Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification was evaluated by digital subtraction angiography or magnetic resonance angiography or computed tomographic angiography. The data related to the procedural techniques, rescue therapy and administration of heparin and tirofiban during EVT were recorded as well.

All EVT procedures were performed by neurointerventionalist with sufficient experience in neurovascular intervention in mechanical thrombectomy (MT) for AIS. Patients who had AIS undergoing EVT were divided into APT group (single APT (SAPT)/ DAPT) and non-APT group.

**Clinical efficacy and safety outcomes**

As a primary safety endpoint, sICH was defined by the European Cooperative Acute Stroke Study III (ECASS-III) trial as evidence of haemorrhage of CT or MR that was felt to be associated with an increase in NIHSS score of >4. Functional independence (mRS 0–2) and mortality at 3-month follow-up were taken as primary efficacy endpoints into consideration. However, secondary efficacy endpoint, successful recanalisation was defined as modified Thrombectomy in Cerebral Infarction (mTICI).

**Statistical analysis**

The patient’s baseline characteristics, including demographic characteristics, vascular risk factors, pathogenesis of stroke according to TOAST classification, clinical and procedural characteristics, stroke categorised as anterior or posterior circulation and OTD, were compared between APT group and non-APT group. The χ² test was used for making comparison between the two groups, while analysis of variance or Kruskal-Wallis test was employed to compare the baseline characteristics and safety and efficacy outcomes at 3-month among SAPT, DAPT and non-APT groups. The ORs with 95% CI of safety and efficacy endpoints (sICH), mTICI grade 2b-3, complete reperfusion (mTICI 3), functional independence (mRS 0–2) and mortality with and without use of APT were evaluated by the logistic regression model. The multivariate models were adjusted for the covariates with p<0.20 in univariate analysis, which included sex, SBP, NIHSS, ASPECTS, atrial fibrillation, hypertension, smoking history, occlusion of the M2 segment of the middle cerebral artery (MCA), IVT, tirofiban and heparin during EVT, general anaesthesia, PTR, MT aspiration, balloon angioplasty and intra-arterial thrombolysis. P<0.05 was considered statistically significant. All statistical analyses were conducted using SPSS software 20.0 software (IBM, Armonk, New York, USA).

**RESULTS**

**Patient’s baseline characteristics**

Of all 917 patients, 2 patients were excluded from the data analysis due to missing baseline data. Finally, 915 patients who underwent EVT with or without receiving APT were analysed (figure 1). The patient’s baseline characteristics are presented in table 1. The median age was 64 (55-72) years old, 611 (66.8%) patients were male, and 199 (21.7%) had received APT. In the DAPT group, ASPECT score on admission was relatively higher and hypertension history was more obvious than those in non-APT and SAPT groups (p<0.05 for all).

The PTR was shorter in the APT group (median (IQR): 70 (44.25 to 110, p=0.033) and more significant in DAPT group (median (IQR): 65 (30 to 90), p=0.001). In the APT group, bridging therapy (IVT followed by EVT) and intra-arterial thrombolysis were less performed compared those in non-APT group ((15.1% vs 29.5%), p=0.000) and (13.6% vs 22.6%), p=0.005)), respectively. On the other hand, the proportions of tirofiban and MT aspiration were found higher in the APT group compared with those in non-APT group (55.8% vs 27.5%, p=0.000) and (14.6% vs 4.3%), p=0.000).

There was no significant difference in vascular risk factors, aetiology of stroke according to TOAST classification, occlusion sites and infarct locations of anterior or posterior circulation.
| Characteristics                              | All patients (n=915) | Non-APT (n=716) | Total (n=199) | SAPT (n=137) | DAPT (n=62) | P value*   | P value†  |
|---------------------------------------------|----------------------|-----------------|---------------|--------------|-------------|------------|------------|
| **Baseline and procedural characteristics** |                      |                 |               |              |             |            |            |
| Age, mean+SD                                | 64 (55–72)           | 64 (55–73)      | 62 (55–69)    | 62 (55–69)   | 62 (57–69.25)| 0.095      | 0.248      |
| Male                                        | 611 (66.8)           | 465 (64.9)      | 146 (73.4)    | 97 (70.8)    | 49 (79)     | **0.026**  | 0.043      |
| SBP, mean+SD                                | 147 (130–161)        | 146 (134–161)   | 148 (132.5–161)| 151.5 (139.5–165.5)| 0.593      | 0.197      |
| Admission NIHSS, median (IQR)               | 14 (9–20)            | 14 (9–20)       | 15 (10–20)    | 15 (11–22)   | 14 (4.75–18.25)| 0.975      | 0.083      |
| ASPECTS (anterior circulation only), median (IQR) | 8 (7–8)            | 8 (7–8)         | 8 (7–8)       | 7 (7–8)      | 8 (7–10)    | **0.78**   | **0.005**  |
| **Vascular risk factors**                   |                      |                 |               |              |             |            |            |
| Atrial fibrillation                        | 164 (17.9)           | 135 (18.9)      | 29 (14.6)     | 23 (16.8)    | 6 (9.7)     | 0.164      | 0.182      |
| Diabetes mellitus                          | 145 (15.8)           | 112 (15.6)      | 33 (16.6)     | 23 (16.8)    | 10 (16.1)   | 0.748      | 0.943      |
| Previous stroke                            | 97 (10.6)            | 75 (10.5)       | 22 (11.1)     | 12 (8.8)     | 10 (16.1)   | 0.814      | 0.286      |
| Hypertension                               | 499 (54.5)           | 378 (52.8)      | 121 (60.8)    | 80 (58.4)    | 41 (66.1)   | **0.045**  | 0.08       |
| Smoking                                    | 311 (34)             | 244 (34.1)      | 67 (33.7)     | 39 (28.5)    | 28 (45.2)   | 0.914      | 0.07       |
| Drinking                                   | 142 (15.5)           | 109 (15.2)      | 33 (16.6)     | 23 (16.8)    | 10 (16.1)   | 0.639      | 0.89       |
| **TOAST classification**                   |                      |                 |               |              |             |            |            |
| Large artery atherosclerosis                | 649 (70.9)           | 501 (70)        | 148 (74.4)    | 102 (74.5)   | 46 (74.2)   | 0.227      | 0.481      |
| Small perforator                           | 0 (0)                |                 |               |              |             |            |            |
| Cardiogenic                                | 168 (18.4)           | 138 (19.3)      | 30 (15.1)     | 22 (16.1)    | 8 (12.9)    | 0.176      | 0.347      |
| Other aetiology                            | 10 (1.1)             | 6 (0.8)         | 4 (2)         | 4 (2.9)      | 0 (0)       | 0.307      | 0.094      |
| Unknown aetiology                          | 88 (9.6)             | 71 (9.9)        | 17 (8.5)      | 9 (6.6)      | 8 (12.9)    | 0.561      | 0.315      |
| **Occlusion site**                         |                      |                 |               |              |             |            |            |
| ICA                                        | 266 (29.1)           | 225 (31.4)      | 62 (31.2)     | 46 (33.6)    | 16 (25.8)   | 0.942      | 0.548      |
| M1                                         | 489 (53.4)           | 267 (37.3)      | 69 (34.7)     | 45 (32.8)    | 24 (38.7)   | 0.498      | 0.58       |
| M2/3                                       | 160 (17.5)           | 66 (9.2)        | 18 (9)        | 9 (6.6)      | 9 (14.5)    | 0.941      | 0.198      |
| ACA                                        | 5 (0.5)              | 3 (0.4)         | 2 (1)         | 2 (1.5)      | 0 (0)       | 0.321      | 0.309      |
| PCA                                        | 17 (1.9)             | 16 (2.2)        | 1 (0.5)       | 0 (0)        | 1 (1.6)     | 0.192      | 0.058      |
| BA                                         | 93 (10.2)            | 70 (8.8)        | 23 (11.6)     | 19 (13.9)    | 4 (6.5)     | 0.462      | 0.217      |
| VA                                         | 93 (10.2)            | 69 (9.6)        | 24 (12.1)     | 16 (11.7)    | 8 (12.9)    | 0.317      | 0.585      |
| Anterior circulation stroke (n%)           | 712 (77.8)           | 561 (78.4)      | 151 (75.9)    | 102 (74.5)   | 49 (79)     | 0.458      | 0.586      |
| Posterior circulation stroke (n%)          | 203 (22.2)           | 155 (21.6)      | 48 (24.1)     | 35 (25.5)    | 13 (21)     | 0.458      | 0.586      |
| OTD time, median (IQR), min                | 180 (105–297)        | 180 (102.25–285)| 180 (120–300) | 180 (120–300)| 176 (88.75–332.5) | 0.55      | 0.822      |
| DTP time, median (IQR), min                | 110 (70–160)         | 110 (70–160)    | 115 (70–170)  | 110 (76–155) | 126.5 (52.25–186.25) | 0.386     | 0.62       |

Continued
| Characteristics                        | All patients (n=915) | Non-APT (n=716) | Total (n=199) | SAPT (n=137) | DAPT (n=62) | P value* | P value† |
|----------------------------------------|----------------------|-----------------|---------------|--------------|-------------|----------|----------|
| PTR time, median (IQR), min           | n=911, 80 (50–112)   | 80 (55–115)     | 70 (44.25–110)| 78 (50–122.5)| 65 (30–90)  | 0.033    | 0.001    |
| OTP time, median (IQR), min           | 315 (220–440)        | 310 (220–430)   | 345 (201–460) | 340 (227–449.5)| 379.5 (180–491.25)| 0.25    | 0.508    |
| OTR time, median (IQR), min           | n=911, 403 (300–540) | 400 (301.5–530) | 417.5 (300–562.5)| 406 (327.5–547.5)| 440 (242.5–602.5) | 0.491    | 0.655    |
| Periprocedural other antithrombotic and anticoagulant |                      |                 |               |              |              |          |          |
| Bridging IVT                          | 241 (26.3)           | 211 (29.5)      | 30 (15.1)     | 19 (13.9)    | 11 (17.7)   | 0.000    | 0.000    |
| Tirofiban                             | 308 (33.7)           | 197 (27.5)      | 111 (55.8)    | 80 (58.4)    | 31 (50)     | 0.000    | 0.000    |
| Heparin during EVT                    | 367 (40.1)           | 283 (39.5)      | 84 (42.2)     | 51 (37.2)    | 33 (53.2)   | 0.494    | 0.081    |
| Procedures characteristics            |                      |                 |               |              |              |          |          |
| General anaesthesia                   | 331 (36.2)           | 239 (33.4)      | 92 (46.2)     | 67 (48.9)    | 25 (40.3)   | 0.001    | 0.002    |
| MT stent retrieval                    | 645 (70.5)           | 497 (69.4)      | 148 (74.4)    | 105 (76.6)   | 43 (69.4)   | 0.175    | 0.231    |
| MT aspiration                         | 60 (6.6)             | 31 (4.3)        | 29 (14.6)     | 21 (15.3)    | 8 (12.9)    | 0.000    | 0.000    |
| Intra-arterial thrombolysis           | 189 (20.7)           | 162 (22.6)      | 27 (13.6)     | 16 (11.7)    | 11 (17.7)   | 0.005    | 0.013    |
| Balloon angioplasty                   | 85 (9.3)             | 66 (9.2)        | 19 (9.5)      | 17 (12.4)    | 2 (3.2)     | 0.887    | 0.083    |
| Stent angioplasty                     | 134 (14.6)           | 109 (15.2)      | 25 (12.6)     | 15 (10.9)    | 10 (16.1)   | 0.348    | 0.407    |

**Boldface type indicates statistical significant.**

*P value between non-APT and APT group.
†P value between non-APT, SAPT and DAPT groups.

ACA, anterior cerebral artery; APT, antiplatelet; ASPECTS, Alberta Stroke Program Early CT score; BA, basilar artery; DAPT, dual antiplatelet; DTP, door-to-puncture; EVT, endovascular treatment; ICA, internal carotid artery; IVT, intravenous thrombolysis; M1, middle cerebral artery M1 segment; M2/3, middle cerebral artery M2/3 segment; NIHSS, National Institutes of Health Stroke Scale score; OTD, onset-to-door; OTP, onset-to-puncture; OTR, onset-to-recanalisation; PCA, posterior cerebral artery; PTR, puncture-to-recanalisation; SAPT, single antiplatelet; SBP, systolic blood pressure; TOAST, trial of ORG 10172 in acute stroke treatment; VA, vertebral artery.
posterior circulation between APT and non-APT groups (p>0.05 for all).

Safety and efficacy outcomes
The safety and efficacy outcomes are shown in tables 2 and 3. Overall, 51 (5.6%) patients developed sICH within 24 hours post-EVT, and no significant difference was noted in sICH incidence between APT group and non-APT group (p>0.05). Further analysis demonstrated that there was no correlation between APT with incidence of sICH (adjusted HR, 0.781; 95% CI 0.103 to 5.944; p=0.811) even after adjusting for some potential confounders.

As shown in tables 2 and 3, 838 (91.6%) patients achieved successful recanalisation (mTICI 2b/3), while complete recanalisation (mTICI 3) could be attained in 642 (70.2%) patients. However, patients in APT group showed more complete recanalisation compared with those in non-APT group (77.4% vs 68.2%, p=0.012), while there was no significant association between APT with successful recanalisation and complete recanalisation even after adjusting for some potential confounders (adjusted HR, 1.410; 95% CI 1.452 to 4.396; p=0.554) even after adjusting for potential confounders.

At 3-month follow-up, excellent outcome (mRS0-1) and functional independence (mRS0-2) could be achieved in 382 (41.7%) and 473 (51.7%) patients, respectively. However, 160 (17.5%) patients died (mRS 6) at 3-month follow-up. In the current research, superior clinical outcomes and lower risk of mortality were found in patients who received DAPT (p=0.046 and p=0.004, respectively). In the current research, we noted that DAPT was associated with excellent outcome (mRS0-1) after adjusting for several potential confounders (adjusted OR, 5.405; 95% CI 1.614 to 18.102; p=0.006). Furthermore, DAPT was significantly correlated with lower risk of mortality (adjusted HR, 0.008; 95% CI 0.000 to 0.441; p=0.019) even after adjusting for potential factors.

Discussion
The present study showed that oral APT has a safety outcome over the risk of sICH in patients who had AIS receiving EVT. DAPT indicated a trend of superior clinical outcome and lower risk of mortality.

There are still controversial issues regarding the safety of APT in patients who had AIS receiving recanalisation therapy. On the other hand, some observational studies reported increased risk of sICH following IVT in patients who underwent APT.1–3 5 On the other hand, some observational studies demonstrated that APT in patients who had AIS receiving recanalisation therapy is not associated with increased risk of sICH even after adjusting for some potential confounders.22–25 Due to limitations in the number of posthoc analyses, cohort studies and research methodology, a previous study could not confirm the safety of APT following EVT.18 In the present study, we found that APT did not increase the risk of sICH. The strength of our finding lies in the larger sample size and adjustment for some potential confounders validating the safety of APT prior to EVT, and previous research studies demonstrated that potential confounders such as, age, vascular risk factors (diabetes mellitus and atrial fibrillation), IVT and intra-arterial thrombolysis are predictors for the increase risk of sICH.22–25

There has been limited evidence for the effects of oral APT preceding EVT on the clinical outcomes. Previous studies showed that APT did not improve
Table 3  Adjusted OR/HR of safety and efficacy outcomes in different treatment groups

| Outcomes                              | Groups  | Adjusted OR/HR (95% CI)   | P value |
|---------------------------------------|---------|--------------------------|---------|
|                                       | Non-APT | Ref                      |         |
| sICH                                  | SAPT    | 0.185 (0.012 to 2.859)   | 0.227   |
|                                       | DAPT    | 17.44 (0.519 to 586.332) | 0.111   |
|                                       | Total APT| 0.781 (0.103 to 5.944)   | 0.811   |
| Successful recanalisation (mTICI 2b/3)| Non-APT | Ref                      |         |
|                                       | SAPT    | 1.883 (0.503 to 7.044)   | 0.347   |
|                                       | DAPT    | 0.531 (0.055 to 5.909)   | 0.583   |
|                                       | Total APT| 1.410 (0.452 to 4.396)   | 0.554   |
| Complete recanalisation (mTICI 3)     | Non-APT | Ref                      |         |
|                                       | SAPT    | 2.586 (1.002 to 6.674)   | 0.05    |
|                                       | DAPT    | 0.396 (0.115 to 1.363)   | 0.142   |
|                                       | Total APT| 1.384 (0.628 to 3.053)   | 0.42    |
| Primary outcome: mRS score at 90 days | Non-APT | Ref                      |         |
|                                       | SAPT    | 0.750 (0.0543 to 1.035)  | 0.080   |
|                                       | DAPT    | 1.662 (1.048 to 2.638)   | 0.031   |
|                                       | Total APT| 0.976 (0.740 to 1.287)   | 0.864   |
| mRS 0–1                               | Non-APT | Ref                      |         |
|                                       | SAPT    | 1.887 (0.806 to 4.417)   | 0.143   |
|                                       | DAPT    | 5.405 (1.614 to 18.102)  | 0.006   |
|                                       | Total APT| 2.605 (1.244 to 5.455)   | 0.011   |
| mRS 0–2                               | Non-APT | Ref                      |         |
|                                       | SAPT    | 1.127 (0.469 to 2.708)   | 0.790   |
|                                       | DAPT    | 2.397 (0.690 to 8.330)   | 0.169   |
|                                       | Total APT| 1.418 (0.661 to 3.041)   | 0.369   |
| mRS 6                                 | Non-APT | Ref                      |         |
|                                       | SAPT    | 1.159 (0.290 to 4.634)   | 0.835   |
|                                       | DAPT    | 0.008 (0.000 to 0.441)   | 0.019   |
|                                       | Total APT| 0.514 (0.147 to 1.797)   | 0.297   |

Adjusted for sex, systolic blood pressure, NIHSS, ASPECTS, atrial fibrillation, hypertension, smoking, other aetiology of TOAST classification, MCA M2/3 segment occlusion site, intravenous thrombolysis, tirofiban, heparin use during, puncture to recanalisation, general anaesthesia, mechanical aspiration and intra-arterial thrombolysis and balloon angioplasty.

aICH, asymptomatic intracranial haemorrhage; APT, antiplatelet; ASPECTS, Alberta Stroke Program Early CT Score; DAPT, dual antiplatelet; MCA, middle cerebral artery; mRS, modified Rankin score; mTICI, modified treatment in cerebral infarction; NIHSS, National Institutes of Health Stroke Scale; SAPT, single antiplatelet; sICH, symptomatic intracranial haemorrhage.

Figure 2  Distribution of mRS scores at 3-month follow-up among non-APT, SAPT and DAPTs. APT, antiplatelet therapy; DAPT, dual APT; mRS, modified Rankin Scale; SAPT, single APT.
patient’s clinical outcomes or reduce the risk mortality at 3-month follow-up although recanalisation could be achieved. 15 17 On the contrary, the results of the current research showed that DAPT is associated with superior clinical outcomes and lower risk of mortality at 3-month follow-up. This difference might be attributed to the point that the rate of successful recanalisation was higher in the current study compared with that in previous studies (91.6% vs 59%–80%, online supplemental table), in which recanalisation is a major predictor of satisfactory outcome following EVT. 36 37

Nevertheless, special care should be taken during interpretation of our results. Overall, the rate of successful recanalisation was slightly higher in the APT group compared with non-APT group. The positive effects of APT have been well described previously (ie, aspirin may inhibit thrombus formation by interfering the inflammatory and immunological processes, 28 29 and the decrease in tissue factor expression and smoother endothelial generated by antiplatelet may facilitate clot removal and prevent recoagulation after initial recanalisation 30 31). In addition, the lack of association between APT and recanalisation in the current study might be related to small sample size in DAPT group, requiring further verification in future studies. Nonetheless, we recommended consolidating the use of APT prior to EVT in patients who had AIS. As revealed in the present study, DAPT might shorten the recanalisation time, accompanying with further clinical outcomes. In case of patients with no history of APT, it is recommended to use glycoprotein IIb/IIIa inhibitors, which have more significant dose-dependent blockade effects on platelet aggregation and thrombosis than aspirin or clopidogrel. 32 33 Moreover, the advantages of glycoprotein IIb/IIIa inhibitors may be more significant for Asian population, in which large artery atherosclerosis is the main aetiology of stroke. 34

Despite the above-mentioned promising result, further randomised controlled trials are required for verification. The strength of the current study lies in the relatively large sample size compared with that in a previous study. Our study has several limitations. First is the uneven distribution between SAPT and DAPT group, which may cause a bias. Second, the EVT and several other rescue therapies were undertaken according to individual experience, which might affect the treatment results. Third, our results cannot be generalised to the global population as the participants enrolled in this study were from China, who have high prevalence of intracranial atherosclerosis. Moreover, the influences of inflammatory factors were not assessed in our research.

CONCLUSION

In summary, oral APT prior to undergoing EVT is safe and may accompany with clinical outcomes. DAPT may be associated with superior clinical outcomes and lower risk of mortality.
21 Luo S, Zhuang M, Zeng W, et al. Intravenous thrombolysis for acute ischaemic stroke: the symptomatic intracranial hemorrhage score. *J Am Heart Assoc* 2016;5. doi:10.1161/JAHA.116.003242. [Epub ahead of print: 05 Dec 2016].

22 Lokeskrawee T, Muengtaweepongsa S, Patumanond J, et al. Prediction of symptomatic intracranial hemorrhage after intravenous thrombolysis in acute ischemic stroke: the symptomatic intracranial hemorrhage score. *J Stroke Cerebrovasc Dis* 2017;26:2622–9.

23 Hao Y, Yang D, Wang H, et al. Predictors for symptomatic intracranial hemorrhage after endovascular treatment of acute ischemic stroke. *Stroke* 2017;48:1203–9.

24 Gattringer T, Muengtaweepongsa S, Patumanond J, et al. Time to redefine success? TICI 3 versus TICI 2B recanalization in middle cerebral artery occlusion treated with thrombectomy. *J Neurointerv Surg* 2017;9:117–21.

25 Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk score. *Stroke* 2020;51:2650–63.

26 Zaidat OO, Yoo AJ, Khatri P, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. *Stroke* 2013;44:2560–63.

27 Kleine JF, Wunderlich S, Zimmer C, et al. Time to redefine success? TICI 3 versus TICI 2B recanalization in middle cerebral artery occlusion treated with thrombectomy. *J Neurointerv Surg* 2017;9:117–21.

28 Pikija S, Magdic J, Lukic A, et al. Antiplatelet usage impacts clot density in acute anterior circulation ischemic stroke. *Int J Mol Sci* 2016;17. doi:10.3390/ijms17091382. [Epub ahead of print: 23 Aug 2016].

29 Boechk-Behrens T, Schubert M, Förschler A, et al. The impact of histological clot composition in embolic stroke. *Clin Neuroradiol* 2016;26:189–97.

30 Amin AR, Vyas P, Attur M, et al. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. *Proc Natl Acad Sci U S A* 1995;92:7926–30.

31 Grotta JC, Welch KM, Fagan SC, et al. Clinical deterioration following improvement in the NINDS rt-PA stroke trial. *Stroke* 2001;32:661–8.

32 Abuimya T, Fitridge R, Mazur C, et al. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. *Stroke* 2000;31:1402–9.

33 Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antplatelet actions. *Blood* 2007;109:2285–92.

34 Yang M, Hao X, Gao F, et al. Low-Dose rescue tirofiban in mechanical thrombectomy for acute cerebral large-artery occlusion. *Eur J Neurol* 2020;27:1056–61.